DrugPatentWatch Database Preview
Litigation Details for Teva Pharmaceuticals USA Inc. v. Sandoz Inc. (D. Del. 2014)
» See Plans and Pricing
Teva Pharmaceuticals USA Inc. v. Sandoz Inc. (D. Del. 2014)
Docket | Start Trial | Date Filed | 2014-09-10 |
Court | District Court, D. Delaware | Date Terminated | 2017-01-30 |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Defendant | Referred To | |
Patents | 6,468,967; 6,852,689; 8,232,250; 8,399,413 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Teva Pharmaceuticals USA Inc. v. Sandoz Inc.
Details for Teva Pharmaceuticals USA Inc. v. Sandoz Inc. (D. Del. 2014)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | 1 | Complaint | entN o. 8 ,232,250 (“t h e’250pa t ent …2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. | External link to document |
0000-00-00 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,232,250; 8,399,413;. (aah) …2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. | External link to document |
2015-10-02 | 99 | Claim Construction Answering Brief | . Del. July 8, 2011)); JA6841 (U.S. Pat. No. 6,468,967, claim 1) & JA6859 (U.S. Pat. No. 6,852,689… original patent on glatiramer acetate expired decades ago. Teva obtained follow-on patents drawn to …necessary for patentability, and holding that “unsolicited assertions of patentability made during prosecution…phrases were not material to patentability. During prosecution of the ’250 patent, claim 1 was amended to…clauses in claims 14-17 of the ’250 patent and claim 7 of the ’413 patent simply state the expected result | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |